{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:33:36Z","timestamp":1794944016980,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Juvenile idiopathic arthritis (JIA) describes heterogenous categories of chronic inflammatory rheumatic conditions of unknown origin in children and adolescents. Epidemiological data in the literature vary, depending on geographic location, ethnicity and the case definition used. We evaluated epidemiology, especially that of the categories defined by the International League of Associations for Rheumatology (ILAR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using data from two different longitudinal health claims databases (WIG2 and InGef) from January 1\n                      <jats:sup>st<\/jats:sup>\n                      , 2013 to December 31\n                      <jats:sup>st<\/jats:sup>\n                      , 2019, we looked at patients aged 2 to 15\u00a0years old with at least one main inpatient or two secondary inpatient\/verified outpatient ICD-10 diagnoses in at least two different quarters within one calendar year. We calculated prevalence and incidence (per 100,000 patients) and extrapolated data to the entire German population, looking at differences in gender and age groups. Additionally, we collected data on \u201cother\u201d not necessary comorbidities in our JIA patient population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 3\u20134 million patients in the databases (respectively) in 2018, we found a total of 546 (WIG2) and 849 (InGef) patients that met our JIA case definition, with an incidence of 34 (29\u201341) and 60 (53\u201367) and prevalence of 133 (122\u2013145) and 168 (157\u2013179). Both incidence and prevalence throughout the age range were mostly higher in females than males, however the difference between females and males increased with increasing age. Of the ILAR categories, oligoarthritis was the most prevalent (70 and 91 per 100,000), with about half of our JIA patients in this category, followed by undifferentiated arthritis (49 and 56 cases per 100,000) and rheumatoid factor negative (RF-) (31 and 39 per 100,000). Incidence in 2018 was the highest in these three categories. Atopic dermatitis, vasomotor and allergic rhinitis, and uveitis were the pre-defined comorbidities seen most often in both databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides current incidence and prevalence JIA data in Germany, contributing to knowledge on burden of disease and tools for healthcare planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-022-00755-x","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T18:02:36Z","timestamp":1668621756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Incidence, prevalence, and comorbidities of juvenile idiopathic arthritis in Germany: a retrospective observational cohort health claims database study"],"prefix":"10.1186","volume":"20","author":[{"given":"Gerd","family":"Horneff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Borchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Klaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Dally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Diesing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-4191","authenticated-orcid":false,"given":"Tonio","family":"Sch\u00f6nfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"755_CR1","doi-asserted-by":"publisher","unstructured":"Barut K, Adrovic A, \u015eahin S, Kasap\u00e7opur \u00d6. Juvenile Idiopathic Arthritis. 2017;34:90\u2013101. https:\/\/doi.org\/10.4274\/balkanmedj.2017.0111.","DOI":"10.4274\/balkanmedj.2017.0111"},{"key":"755_CR2","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol."},{"key":"755_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrrheum.2009.209","volume":"5","author":"C Macaubas","year":"2009","unstructured":"Macaubas C, Nguyen K, Milojevic D, Park JL, Mellins ED. Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol. 2009;5:616\u201326. https:\/\/doi.org\/10.1038\/nrrheum.2009.209.","journal-title":"Nat Rev Rheumatol"},{"key":"755_CR4","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(11)60244-4.","journal-title":"Lancet"},{"key":"755_CR5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/acr.21709","volume":"64","author":"BL Nordstrom","year":"2012","unstructured":"Nordstrom BL, Mines D, Gu Y, Mercaldi C, Aquino P, Harrison MJ. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken). 2012;64:1357\u201364. https:\/\/doi.org\/10.1002\/acr.21709.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"755_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12969-020-00426-9","volume":"18","author":"TA Simon","year":"2020","unstructured":"Simon TA, Harikrishnan GP, Kawabata H, Singhal S, Brunner HI, Lovell DJ. Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study. Pediatr Rheumatol Online J. 2020;18:43. https:\/\/doi.org\/10.1186\/s12969-020-00426-9.","journal-title":"Pediatr Rheumatol Online J"},{"key":"755_CR7","first-page":"1991","volume":"25","author":"RE Petty","year":"1998","unstructured":"Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25:1991\u20134.","journal-title":"J Rheumatol"},{"key":"755_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019;71:717\u201334. https:\/\/doi.org\/10.1002\/acr.23870.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"755_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1542\/peds.98.1.84","volume":"98","author":"PJ Manners","year":"1996","unstructured":"Manners PJ, Diepeveen DA. Prevalence of juvenile chronic arthritis in a population of 12-year-old children in urban Australia. Pediatrics. 1996;98:84\u201390.","journal-title":"Pediatrics"},{"key":"755_CR10","first-page":"379","volume":"29","author":"D Kurahara","year":"2002","unstructured":"Kurahara D, Tokuda A, Grandinetti A, Najita J, Ho C, Yamamoto K, et al. Ethnic differences in risk for pediatric rheumatic illness in a culturally diverse population. J Rheumatol. 2002;29:379\u201383.","journal-title":"J Rheumatol"},{"key":"755_CR11","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1186\/1471-2407-14-634","volume":"14","author":"VC Kok","year":"2014","unstructured":"Kok VC, Horng J-T, Huang J-L, Yeh K-W, Gau J-J, Chang C-W, Zhuang L-Z. Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis. BMC Cancer. 2014;14:634. https:\/\/doi.org\/10.1186\/1471-2407-14-634.","journal-title":"BMC Cancer"},{"key":"755_CR12","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1002\/art.22709","volume":"56","author":"RK Saurenmann","year":"2007","unstructured":"Saurenmann RK, Rose JB, Tyrrell P, Feldman BM, Laxer RM, Schneider R, Silverman ED. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum. 2007;56:1974\u201384. https:\/\/doi.org\/10.1002\/art.22709.","journal-title":"Arthritis Rheum"},{"key":"755_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s00393-016-0094-2","volume":"75","author":"A Zink","year":"2016","unstructured":"Zink A, Albrecht K. Wie h\u00e4ufig sind muskuloskeletale Erkrankungen in Deutschland? [How frequent are musculoskeletal diseases in Germany?]. Z Rheumatol. 2016;75:346\u201353. https:\/\/doi.org\/10.1007\/s00393-016-0094-2.","journal-title":"Z Rheumatol"},{"key":"755_CR14","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, Martini A. Arthritis 3 Juvenile idiopathic arthritis. Lancet (London, England). 2011;377:2138\u201387.","journal-title":"Lancet (London, England)."},{"key":"755_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81:112\u20137. https:\/\/doi.org\/10.1016\/j.jbspin.2013.09.003.","journal-title":"Joint Bone Spine"},{"key":"755_CR16","first-page":"99","volume":"16","author":"N Moe","year":"1998","unstructured":"Moe N, Rygg M. Epidemiology of juvenile chronic arthritis in northern Norway: a ten-year retrospective study. Clin Exp Rheumatol. 1998;16:99\u2013101.","journal-title":"Clin Exp Rheumatol"},{"key":"755_CR17","volume-title":"Epidemiologie der juvenilen idiopathischen Arthritis (JIA) in der ambulanten Versorgung \u2013 eine Analyse anhand bundesweiter vertrags\u00e4rztlicher Abrechnungsdaten der Jahre 2009 bis 2015: Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in Deutschland (Zi)","author":"S Thomschke","year":"2018","unstructured":"Thomschke S, Schulz M, B\u00e4tzing J. Epidemiologie der juvenilen idiopathischen Arthritis (JIA) in der ambulanten Versorgung \u2013 eine Analyse anhand bundesweiter vertrags\u00e4rztlicher Abrechnungsdaten der Jahre 2009 bis 2015: Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in Deutschland (Zi). 2018."},{"key":"755_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11657-022-01156-z","volume":"17","author":"J O'Kelly","year":"2022","unstructured":"O\u2019Kelly J, Bartsch R, Kossack N, Borchert J, Pignot M, Hadji P. Real-world effectiveness of osteoporosis treatments in Germany. Arch Osteoporos. 2022;17:119. https:\/\/doi.org\/10.1007\/s11657-022-01156-z.","journal-title":"Arch Osteoporos"},{"key":"755_CR19","doi-asserted-by":"publisher","first-page":"adv00309","DOI":"10.2340\/00015555-3655","volume":"100","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Ketz M, Kossack N, Akumo D, Pignot M, Gabriel S, Chavda R. Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: a Claims Database Analysis. Acta Derm Venereol. 2020;100:adv00309. https:\/\/doi.org\/10.2340\/00015555-3655.","journal-title":"Acta Derm Venereol"},{"key":"755_CR20","doi-asserted-by":"publisher","unstructured":"Holthuis E, Smits E, Spentzouris G, Beier D, Enders D, Gini R, et al. Increased risk of stroke Due to Non-adherence and Non-persistence with Direct Oral Anticoagulants (DOACs): Real-world analyses using a nested case-control study from The Netherlands, Italy and Germany. Drugs - Real World Outcomes. 2022:1\u201311.:https:\/\/doi.org\/10.1007\/s40801-022-00317-3.","DOI":"10.1007\/s40801-022-00317-3"},{"key":"755_CR21","unstructured":"Sanofi-Aventis Deutschland GmbH. Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 351 SGB V Dupilumab, Modul 3 E. Gemeinsamer Bundesausschuss. 2018. https:\/\/www.g-ba.de\/downloads\/92-975-4353\/2020-12-16_Modul3E_Dupilumab.pdf. Accessed 1 Nov 2022."},{"key":"755_CR22","volume-title":"Dossier zur Nutzenbewertung von Dupilumab","author":"Gemeinsame Bundesausschuss","year":"2018","unstructured":"Gemeinsame Bundesausschuss. Dossier zur Nutzenbewertung von Dupilumab. 2018."},{"key":"755_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol Drug Saf. 2016;25:106\u20139. https:\/\/doi.org\/10.1002\/pds.3895.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"755_CR24","doi-asserted-by":"publisher","unstructured":"Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25:2\u201310. https:\/\/doi.org\/10.1002\/pds.3891.","DOI":"10.1002\/pds.3891"},{"key":"755_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00296-014-3142-8","volume":"35","author":"E Stringer","year":"2015","unstructured":"Stringer E, Bernatsky S. Validity of juvenile idiopathic arthritis diagnoses using administrative health data. Rheumatol Int. 2015;35:575\u20139. https:\/\/doi.org\/10.1007\/s00296-014-3142-8.","journal-title":"Rheumatol Int"},{"key":"755_CR26","unstructured":"Statistisches Bundesamt. Statistik zur Fortschreibung des Bev\u00f6lkerungsstandes: GENESIS Online Datenbank. 2020. https:\/\/www-genesis.destatis.de\/genesis\/\/online?operation=statistic&code=12411&levelindex=0&levelid=1602584789010#abreadcrumb. Accessed 13 Oct 2020."},{"key":"755_CR27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/(SICI)1097-0258(19970415)16:7<791::AID-SIM500>3.0.CO;2-#","volume":"16","author":"MP Fay","year":"1997","unstructured":"Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med. 1997;16:791\u2013801. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(19970415)16:7%3c791::AID-SIM500%3e3.0.CO;2-#.","journal-title":"Stat Med"},{"key":"755_CR28","first-page":"1520","volume":"29","author":"PJ Manners","year":"2002","unstructured":"Manners PJ, Bower C. Worldwide prevalence of juveline arthritis - why does it vary so much? J Rheumatol. 2002;29:1520\u201330.","journal-title":"J Rheumatol."},{"key":"755_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/CEOR.S197117","volume":"11","author":"A Marshall","year":"2019","unstructured":"Marshall A, Gupta K, Pazirandeh M, Bonafede M, McMorrow D. Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis. Clinicoecon Outcomes Res. 2019;11:361\u201371. https:\/\/doi.org\/10.2147\/CEOR.S197117.","journal-title":"Clinicoecon Outcomes Res"},{"key":"755_CR30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13075-019-1994-8","volume":"21","author":"E Berthold","year":"2019","unstructured":"Berthold E, M\u00e5nsson B, Kahn R. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther. 2019;21:218. https:\/\/doi.org\/10.1186\/s13075-019-1994-8.","journal-title":"Arthritis Res Ther"},{"key":"755_CR31","unstructured":"Gemeinsamer Bundesausschuss. 2021_09_13_Modul3A_Tofacitinib: Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. www.g-ba.de."},{"key":"755_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13075-018-1588-x","volume":"20","author":"M Listing","year":"2018","unstructured":"Listing M, M\u00f6nkem\u00f6ller K, Liedmann I, Niewerth M, Sengler C, Listing J, et al. The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON). Arthritis Res Ther. 2018;20:106. https:\/\/doi.org\/10.1186\/s13075-018-1588-x.","journal-title":"Arthritis Res Ther"},{"key":"755_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46:190\u20137. https:\/\/doi.org\/10.3899\/jrheum.180168.","journal-title":"J Rheumatol"},{"key":"755_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13023-017-0586-4","volume":"12","author":"L Aoust","year":"2017","unstructured":"Aoust L, Rossi-Semerano L, Kon\u00e9-Paut I, Dusser P. Time to diagnosis in juvenile idiopathic arthritis: a french perspective. Orphanet J Rare Dis. 2017;12:43. https:\/\/doi.org\/10.1186\/s13023-017-0586-4.","journal-title":"Orphanet J Rare Dis"},{"key":"755_CR35","first-page":"1035","volume":"41","author":"O Kasapcopour","year":"2004","unstructured":"Kasapcopour O, Yologlu N. Uveitis and anti nuclear antibody positivity in children with juvenile idiopathic arthritis. Indian Pediatr. 2004;41:1035\u20139.","journal-title":"Indian Pediatr."},{"key":"755_CR36","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10067-011-1832-0","volume":"30","author":"E Tarakci","year":"2011","unstructured":"Tarakci E, Yeldan I, Kaya Mutlu E, Baydogan SN, Kasapcopur O. The relationship between physical activity level, anxiety, depression, and functional ability in children and adolescents with juvenile idiopathic arthritis. Clin Rheumatol. 2011;30:1415\u201320. https:\/\/doi.org\/10.1007\/s10067-011-1832-0.","journal-title":"Clin Rheumatol"},{"key":"755_CR37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/art.22381","volume":"56","author":"RK Saurenmann","year":"2007","unstructured":"Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, Silverman ED. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. 2007;56:647\u201357. https:\/\/doi.org\/10.1002\/art.22381.","journal-title":"Arthritis Rheum"},{"key":"755_CR38","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/CLEP.S315888","volume":"13","author":"K Hagenstr\u00f6m","year":"2021","unstructured":"Hagenstr\u00f6m K, Sauer K, Mohr N, Dettmann M, Glaeske G, Petersen J, et al. Prevalence and medications of atopic dermatitis in Germany: claims data analysis. Clin Epidemiol. 2021;13:593\u2013602. https:\/\/doi.org\/10.2147\/CLEP.S315888.","journal-title":"Clin Epidemiol"},{"key":"755_CR39","volume-title":"Stadt-Land-Unterschiede in der Verbreitung von Heuschnupfen in Deutschland: Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in Deutschland (Zi)","author":"J Holstiege","year":"2021","unstructured":"Holstiege J, Akmatov MK, Dammertz L, Heuer J, Kohring C, B\u00e4tzing J. Stadt-Land-Unterschiede in der Verbreitung von Heuschnupfen in Deutschland: Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in Deutschland (Zi). 2021."},{"key":"755_CR40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3109\/03009741003685608","volume":"39","author":"H Pohjankoski","year":"2010","unstructured":"Pohjankoski H, Kautiainen H, Kotaniemi K, Korppi M, Savolainen A. Autoimmune diseases in children with juvenile idiopathic arthritis. Scand J Rheumatol. 2010;39:435\u20136. https:\/\/doi.org\/10.3109\/03009741003685608.","journal-title":"Scand J Rheumatol"},{"key":"755_CR41","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3899\/jrheum.140472","volume":"42","author":"D Barthel","year":"2015","unstructured":"Barthel D, Ganser G, Kuester R-M, Onken N, Minden K, Girschick HJ, et al. Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol. 2015;42:2160\u20135. https:\/\/doi.org\/10.3899\/jrheum.140472.","journal-title":"J Rheumatol"},{"key":"755_CR42","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00393-014-1397-9","volume":"73","author":"G Horneff","year":"2014","unstructured":"Horneff G, Minden K, Foeldvari I, Onken N, Windschall D, Hospach A, et al. Aktuelles aus dem BIKER-register. [Current news from the BIKER register]. Z Rheumatol. 2014;73:897\u2013906. https:\/\/doi.org\/10.1007\/s00393-014-1397-9.","journal-title":"Z Rheumatol"},{"key":"755_CR43","doi-asserted-by":"publisher","first-page":"e0243774","DOI":"10.1371\/journal.pone.0243774","volume":"16","author":"I Kern","year":"2021","unstructured":"Kern I, Schoffer O, Kiess W, Henker J, Laa\u00df MW, Winkler U, et al. Incidence trends of pediatric onset inflammatory bowel disease in the years 2000\u20132009 in Saxony, Germany-first results of the Saxon Pediatric IBD Registry. PLoS ONE. 2021;16:e0243774. https:\/\/doi.org\/10.1371\/journal.pone.0243774.","journal-title":"PLoS ONE"},{"key":"755_CR44","doi-asserted-by":"publisher","first-page":"265954","DOI":"10.1155\/2014\/265954","volume":"2014","author":"C Giannini","year":"2014","unstructured":"Giannini C, Mohn A, Chiarelli F. Growth abnormalities in children with type 1 diabetes, juvenile chronic arthritis, and asthma. Int J Endocrinol. 2014;2014:265954. https:\/\/doi.org\/10.1155\/2014\/265954.","journal-title":"Int J Endocrinol"},{"key":"755_CR45","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1002\/art.39129","volume":"67","author":"J Miller","year":"2015","unstructured":"Miller J, Ponsonby A-L, Pezic A, Kemp A, Piper SE, Akikusa JD, et al. Sibling exposure and risk of juvenile idiopathic arthritis. Arthritis Rheumatol. 2015;67:1951\u20138. https:\/\/doi.org\/10.1002\/art.39129.","journal-title":"Arthritis Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00755-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-022-00755-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00755-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T18:09:43Z","timestamp":1668622183000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-022-00755-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1186\/s12969-022-00755-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"10 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Data in the databases are from healthcare claims, collected according to the 10th chapter of book V of social code in Germany (SGB V, Sozialgesetzbuch), and provided in anonymous form, solely for research purposes. Only WIG2 and InGef employees were granted access to the data, and only aggregated results were generated and presented.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors had complete autonomy for the process of designing the study, carrying out the analyses, interpreting the results and writing the manuscript. PK, CH, HD are employees of Pfizer Pharma GmbH. JB, RH, JD and TS are all employees of WIG2 GmbH, which is an independent institute and paid consultant to Pfizer Pharma GmbH for designing the study, carrying out the analyses, interpreting the results and writing the manuscript. GH received an honorarium from Pfizer Pharma GmbH in connection with designing the study and interpreting the results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}